

Message

From: Green, Joseph J. [JGreen@KelleyDrye.com]
Sent: 1/8/2018 7:00:53 PM
To: Hebert, John [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=07f9bbc7c7c4219aa78a9618f7ead54-John D. Hebert]
CC: Weiss, Steven [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=6ce04987a3784f21985f65e96c220b84-Weiss, Steven]; Keigwin, Richard [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=151baabb6a2246a3a312f12a706c0a05-Richard P Keigwin Jr]; Hughes, Hayley [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=d98153a3667544ce81b60dd0b1ecbd0d-Hughes, Hay]; Willis, Kristen [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=0b437bee32204a51aed37522b09153f3-Willis, Kri]; Beck, Nancy [/o=ExchangeLabs/ou=Exchange Administrative Group (FYDIBOHF23SPDLT)/cn=Recipients/cn=168ecb5184ac44de95a913297f353745-Beck, Nancy]
Subject: RE: Draft Charge Questions - Antimicrobial Copper Clinical Trial Expert Panel Review
Attachments: Proposed EPA Cover Letter to Clinical Trial Expert Panel Reviewers v1.docx

Hi all – Following up on last week’s message and forwarding a proposed draft cover letter for sending the charge questions and other materials to prospective panel reviewers. Please let us know if you have any questions or if you would like to discuss.

CDA appreciates your continued efforts in moving forward with review and consideration of the copper clinical trial data and associated claims.

Regards,
Joe

JOSEPH J. GREEN
Special Counsel
Kelley Drye & Warren LLP
(202) 342-8849
JGreen@KelleyDrye.com
Counsel to the Copper Development Association

From: Green, Joseph J.
Sent: Friday, January 05, 2018 10:02 AM
To: 'Hebert, John' <Hebert.John@epa.gov>
Cc: Weiss, Steven <Weiss.Steven@epa.gov>; Keigwin, Richard <Keigwin.Richard@epa.gov>; Hughes, Hayley <hughes.hayley@epa.gov>; Willis, Kristen <Willis.Kristen@epa.gov>; 'beck.nancy@epa.gov' <beck.nancy@epa.gov>
Subject: RE: Draft Charge Questions - Antimicrobial Copper Clinical Trial Expert Panel Review

Hi John –

Thanks again for sending the draft charge questions. In the attached letter and red-line document, CDA has a few suggestions on the questions and some recommendations for moving forward, including a suggested timeline to help maintain progress in getting the review of the copper clinical trial underway and completed. We do hope that the process can get started in the next week or so (by January 15) with sending out the initial communication from EPA to prospective panel members, as noted in our letter. To that end, I will be forwarding a suggested cover letter in the next day or so.

Please let us know if you have any questions or need any additional information, and keep us posted on how things proceed.

Also, best wishes with the new posting. We have appreciated working with you and look forward to continuing to do so.

Regards,
Joe

JOSEPH J. GREEN
Special Counsel
Kelley Drye & Warren LLP
Washington Harbour
3050 K Street NW, Suite 400
Washington, DC 20007
Tel: (202) 342-8849
JGreen@KelleyDrye.com

WWW.KELLEYDRYE.COM

From: Hebert, John [<mailto:Hebert.John@epa.gov>]
Sent: Friday, December 15, 2017 3:52 PM
To: Green, Joseph J. <JGreen@KelleyDrye.com>
Cc: Weiss, Steven <Weiss.Steven@epa.gov>; Keigwin, Richard <Keigwin.Richard@epa.gov>; Hughes, Hayley <hughes.hayley@epa.gov>; Willis, Kristen <Willis.Kristen@epa.gov>
Subject: Draft Charge Questions

Hello Joe – Please see the attached draft charge questions. Along with charge questions, we intend to provide our federal partners with a white paper that describes the general registration process including efficacy data requirements for products making public health claims. Please let me know if you have any questions.

Regards,
John

John Hebert, Chief
Registration Management Branch I
Antimicrobials Division
Office of Pesticide Programs
Environmental Protection Agency
(703) 308-6249
hebert.john@epa.gov

The information contained in this E-mail message is privileged, confidential, and may be protected from disclosure; please be aware that any other use, printing, copying, disclosure or dissemination of this communication may be subject to legal restriction or sanction. If you think that you have received this E-mail message in error, please reply to the sender.

This E-mail message and any attachments have been scanned for viruses and are believed to be free of any virus

or other defect that might affect any computer system into which it is received and opened. However, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by Kelley Drye & Warren LLP for any loss or damage arising in any way from its use.